Marvel Biosciences Past Earnings Performance
Past criteria checks 0/6
Marvel Biosciences's earnings have been declining at an average annual rate of -15.2%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-15.2%
Earnings growth rate
28.7%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Apr 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Marvel Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Apr 24 | 0 | -2 | 1 | 1 |
| 31 Jan 24 | 0 | -3 | 1 | 1 |
| 31 Oct 23 | 0 | -3 | 1 | 1 |
| 31 Jul 23 | 0 | -2 | 1 | 1 |
| 30 Apr 23 | 0 | -2 | 1 | 0 |
| 31 Jan 23 | 0 | -2 | 1 | 0 |
| 31 Oct 22 | 0 | -2 | 1 | 1 |
| 31 Jul 22 | 0 | -3 | 1 | 1 |
| 30 Apr 22 | 0 | -4 | 1 | 1 |
| 31 Jan 22 | 0 | -4 | 1 | 1 |
| 31 Oct 21 | 0 | -3 | 1 | 1 |
| 31 Jul 21 | 0 | -3 | 1 | 1 |
| 30 Apr 21 | 0 | -1 | 1 | 1 |
| 31 Jan 21 | 0 | -1 | 1 | 0 |
| 31 Oct 20 | 0 | -1 | 1 | 0 |
| 31 Jul 20 | 0 | -1 | 1 | 0 |
Quality Earnings: MRVL is currently unprofitable.
Growing Profit Margin: MRVL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MRVL is unprofitable, and losses have increased over the past 5 years at a rate of 15.2% per year.
Accelerating Growth: Unable to compare MRVL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MRVL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: MRVL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.